1. Functional symptoms in dermatology: Part 1. (1st January 2020) Authors: Ball, S. L.; Howes, C.; Affleck, A. G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 1(2020) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Functional symptoms in dermatology: Part 1. (27th August 2019) Authors: Ball, S. L.; Howes, C.; Affleck, A. G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 1(2020) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Functional symptoms in dermatology: Part 2. (1st January 2020) Authors: Ball, S.L.; Howes, C.; Affleck, A.G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 1(2020) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Functional symptoms in dermatology: Part 2. (29th August 2019) Authors: Ball, S.L.; Howes, C.; Affleck, A.G. Journal: Clinical and experimental dermatology Issue: Volume 45:Number 1(2020) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma. (December 2016) Authors: Diallo, B.; Massonnet, G.; El-Botty, R.; Raymondie, C.; Howes, C.; Wilson, J.; Smith, A.; Roman-Roman, S.; Smith, P.; Davies, E.; Decaudin, D.; Némati, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗